List of works - Sebastien Jeay

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

scientific article published on 12 May 2015

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

scientific article

B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain

scientific article published on 01 April 2003

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

scientific article

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

scientific article published on 17 November 2016

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

scientific article

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument

scientific article

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode

scientific article

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

scientific article published on 22 August 2018

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

scientific article published on 22 May 2016

Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein

scientific article published on 01 July 1999

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells

scientific article published on 22 September 2016

Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation

scientific article published on 01 September 2000

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

scientific article published on 26 August 2018

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

scientific article

Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

scientific article

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

scientific article published on 26 February 2016

Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.

scientific article published on May 2004

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

scientific article published on 6 March 2017

The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53 - p21 - Rb - E2F1 Cascade in the p53wildtype Neuroendocrine Tumor Cell Line GOT1.

scientific article published on 21 November 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

scientific article published on 11 July 2016

The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells.

scientific article published on 23 July 2004

The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.

scientific article published on February 2007

List of works by Sebastien Jeay

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells

Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53 - p21 - Rb - E2F1 Cascade in the p53wildtype Neuroendocrine Tumor Cell Line GOT1.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells.

The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.